Pictet Asset Management Holding SA Sells 42,929 Shares of ResMed Inc. $RMD

Key Points

• Pictet Asset Management cut its ResMed stake by 36.8%, selling 42,929 shares and leaving it with 73,650 shares worth about $17.7 million, while hedge funds and institutions collectively own roughly 55% of the stock.
• ResMed beat Q3 expectations (EPS $2.86 vs. $2.79; revenue $1.43B, up 10.8% YoY) and reported margin expansion, but the stock fell and analyst reactions are mixed—average rating "Moderate Buy" with price targets ranging from ~$227 to $321.
• The company declared a quarterly dividend of $0.60 (1.2% yield, payable June 18) as insiders have been selling recently (21,023 shares sold in the past three months), though insider ownership remains low (~0.65%).

Pictet Asset Management Holding SA lowered its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 36.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,650 shares of the medical equipment provider's stock after selling 42,929 shares during the period. Pictet Asset Management Holding SA owned 0.05% of ResMed worth $17,742,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. SJS Investment Consulting Inc. lifted its stake in ResMed by 1,433.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 86 shares in the last quarter. Imprint Wealth LLC purchased a new position in shares of ResMed during the third quarter valued at about $26,000. WFA of San Diego LLC purchased a new position in shares of ResMed during the second quarter valued at about $26,000. ORG Partners LLC increased its holdings in shares of ResMed by 181.6% in the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 69 shares during the last quarter. Finally, Sunbelt Securities Inc. bought a new stake in shares of ResMed in the third quarter worth about $31,000. Hedge funds and other institutional investors own 54.98% of the company's stock.

ResMed Stock Down 4.0%

Shares of NYSE:RMD opened at $205.17 on Friday. The company has a market cap of $29.89 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.41 and a beta of 0.85. ResMed Inc. has a 12 month low of $198.64 and a 12 month high of $293.81. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $233.35 and a 200 day moving average price of $246.69.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.07. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The company had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $1.42 billion. During the same period in the previous year, the firm posted $2.37 earnings per share. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. As a group, equities research analysts predict that ResMed Inc. will post 11.05 earnings per share for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 14th. This represents a $2.40 annualized dividend and a dividend yield of 1.2%. ResMed's payout ratio is currently 23.74%.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction on Monday, February 9th. The shares were sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the completion of the transaction, the chief executive officer directly owned 466,223 shares of the company's stock, valued at $127,642,532.94. The trade was a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 21,023 shares of company stock worth $5,230,857. Corporate insiders own 0.65% of the company's stock.

Wall Street Analyst Weigh In

RMD has been the subject of a number of research reports. Weiss Ratings lowered ResMed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, March 19th. Robert W. Baird set a $225.00 price objective on ResMed in a research note on Friday. Wells Fargo & Company decreased their price objective on ResMed from $270.00 to $227.00 and set an "equal weight" rating on the stock in a report on Friday. Stifel Nicolaus increased their target price on ResMed from $260.00 to $265.00 and gave the company a "hold" rating in a research report on Friday, January 30th. Finally, JPMorgan Chase & Co. started coverage on shares of ResMed in a report on Wednesday, April 15th. They issued an "overweight" rating for the company. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $286.18.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

ResMed Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.